

CURRICULUM VITAE

I. PERSONAL INFORMATION

AGNIESZKA DOROTA CZECHOWICZ

Address: Rm. 2351, Biomedical Innovations Building
240 Pasteur Dr., Stanford, CA. 94304
E-Mail: aneeshka@stanford.edu
Office Phone: 650-497-2218
Cell Phone: 650-387-1102

II. ACADEMIC HISTORY

A. Education and Training

09/2001-03/2004 **B.S.**, Biological Sciences with Honors, Chemistry minor. Stanford University, Stanford, CA. Honors Thesis: Development of a robust human adaptive immune system in CD34+ enriched peripheral blood transplanted mice through use of anti-murine-c-kit monoclonal ACK2. Degree granted 6/2005. Student representative to Stanford University Faculty Senate and Board of Trustees.

06/2006-06/2010 **Ph.D.**, Developmental Biology, Stanford University, Stanford, CA. Advisor: Prof. Irving L. Weissman, M.D.. Thesis: *Gaining Access to the HSC Niche - Novel Non-Myeloablative Conditioning Approaches*.

06/2006-01/2012 **M.D.**, Scholarly Concentration Molecular Basis of Medicine, Stanford University School of Medicine, Stanford, CA. Student Body President.

07/2009-08/2009 Summer Institute of Entrepreneurship, Stanford University, Graduate School of Business, Stanford, CA. Mini-MBA program focused on new venture formation.

01/2012-12/2014 Pediatric Residency, Categorical and Integrated Research Tracks, Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Boston, MA. Continuity Clinics in Pediatrics and Pediatric Genetics.

01/2012-02/2017 Post-Doctoral Research Fellowship, Stem Cell Biology, Boston Children's Hospital, Boston, MA. Advisor: Prof. Derrick Rossi.

01/2015-02/2017 Pediatric Hematology/Oncology/Stem Cell Transplant Fellowship Year I-II, Dana Farber Cancer Institute/ Boston Children's Hospital, Boston, MA. Sub-focus in Stem Cell Transplant.

02/2017-12/2017 Pediatric Hematology/Oncology/Stem Cell Transplant Fellowship Year III, Stanford University/Stanford Children's Health, Stanford, CA. Sub-focus in Bone Marrow Failure.

B. Current Licensure and Certification

2014 Medical Licensure, Commonwealth of Massachusetts No. 261532, expired 8/2017.
2016 Medical Licensure, Medical Board of California No. A146625, expiration 8/2024.
2016 DEA Licensure, registration no FC6372471, expiration 8/2024.
2021 General Pediatrics Board Certified.
2023 Pediatric Hematology/Oncology Board Certified.

III. ACADEMIC AND PROFESSIONAL APPOINTMENTS

2018-present **Assistant Professor**, Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA. Direct a basic science and translational research laboratory composed of 3 Postdoctoral fellows, 1 M.D./Ph.D. student, 1 Ph.D. student, 1 M.S. students, 1 undergraduate student, 3 Research Scientists and 1 Research Technician.

2018-present **Member**, Stanford University Institute for Stem Cell Biology and Regenerative Medicine

2018-present **Co-lead**, Blood Stem Cell Engineering and Transplantation Platform, Stanford Center for Definitive and Curative Medicine.

2018-present **Member**, Stanford Center for Definitive and Curative Medicine

2018-present **Member**, Stanford University Maternal and Child Health Research Institute

2018-present **Member**, Stanford University Diabetes Research Center
 2018-present **Member**, Stanford University Immunology Program
 2018-present **Member**, Stanford University Bio-X
 2018-present **Faculty Mentor**, T32 Training Grant in Medical Scientist Training Program
 2018-present **Faculty Mentor**, T32 Training Grant in Pediatric Nonmalignant Hematology and Stem Cell Biology

IV. HONORS AND AWARDS

2001 Summer Student Award, American Society of Hematology (ASH)
 2005 Achaeur Award for Outstanding Honors Presentation, Stanford University
 2005 Firestone Medal for Excellence in Undergraduate Research, Stanford University
 2005 Honors in Biological Sciences, Stanford University
 2006-2009 Medical Scientist Fellowship, Stanford University Medical Scholars Program
 2007 Young Scientist Travel Grant, International Congress of Immunology
 2007 Trainee Research Award, American Society of Hematology (ASH)
 2007 Late-Breaking Abstract Recipient, American Society of Hematology (ASH)
 2007 Invitee Transplantation Press Conference, American Society of Hematology (ASH)
 2008-2009 Research Training Fellowship, Howard Hughes Medical Institute (HHMI)
 2008-2010 Soros Fellowship, Paul & Daisy Soros Foundation
 2010 Presenter Travel Award, American Society of Hematology (ASH)
 2011 ISSCR Scholarship, California Institute of Regenerative Medicine
 2014 Fred Lovejoy Award, Boston Children's Hospital
 2014 Delegate, International Summit of Achievement, Academy of Achievement
 2015 Potter Fellowship, Boston Children's Hospital / Dana Farber Cancer Institute
 2016 Abstract Achievement Award, American Society of Hematology (ASH)
 2018 Lorry I. Lokey Faculty Scholar, Stanford University School of Medicine
 2019 Baxter Faculty Scholar, Donald E. and Delia B. Baxter Foundation
 2020 New Investigator Award, American Society of Transplantation and Cell Therapy (ASTCT)
 2020 Young Investigator Award, National Comprehensive Cancer Network (NCCN)
 2020 Best Pre-clinical Publication Award, World ADC
 2021 Bronze Prize, Custom Animal Model Awards (CAMA), Taconic-Cyagen
 2021 Outstanding Poster Presentation Award, American Society of Gene and Cell Therapy (ASGCT)
 2022 David B. Frohnmayer Early Career Investigator Award, Fanconi Anemia Research Foundation (FARF)
 2022 Junior Faculty Scholar Award, American Society of Hematology (ASH)
 2022 Ernest McCulloch and James Till Award for the Best Basic Science article, Transplantation and Cell Therapy (TCT).
 2023 Second Place Best PEDS Abstract, Transplantation and Cell Therapy (TCT)
 2024 Outstanding New Investigator Award, American Society of Gene and Cell Therapy (ASGCT)

V. SCHOLARLY PUBLICATIONS

A. Original Articles: Peer-Reviewed (20 Published, 4 in Review/Submission)

1. **Czechowicz A**, Kraft D, Weissman IL, Bhattacharya D. "Efficient Transplantation via Antibody-based Clearance of Hematopoietic Stem Cell Niches." Science. 318(5854):1296-9. 2007.
2. Rossi DJ, Seita J, **Czechowicz A**, Bhattacharya D, Bryder D, Weissman IL. "Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging." Cell Cycle. 6(19):2371-6. 2007.
3. Bhattacharya D*, **Czechowicz A***, Ooi L, Rossi D, Bryder D, Weissman IL. "Niche Recycling Through Division-Independent Egress of Hematopoietic Stem Cells." Journal of Experimental Medicine. Nov 23;206(12):2837-50. 2009. [*Co-first author*]

4. Ahn GO, Tseng D, Liao CH, Dorie MJ, **Czechowicz A**, Brown JM. “Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment.” Proc Natl Acad Sci. May 4;107(18):8363-8. 2010.
5. Edris B, Willingham S, Weiskopf K, Volkmer A, Volkmer J, Muhlenberg T, Montgomery K, Contreras-Trujillo H, **Czechowicz A**, Shizuru S, Fletcher J, West R, Weissman I, Van de Rijn M. “Anti-KIT Monoclonal Antibody SR1 Inhibits Growth In Vitro and In Xenotransplantation Models.” Proc Natl Acad Sci. Feb 26;110(9):3501-6. 2013.
6. Derderian C, Togarrati P, King C, Moradi P, Reynaud D, Weissman I, **Czechowicz A**, and MacKenzie T. “In Utero Depletion of Fetal Host Hematopoietic Stem Cells Improves Engraftment Following Neonatal Transplantation In Mice.” Blood. 2014 Aug 7;124(6):973-80.
7. Dvorak CC, Horn BN, Puck JM, Adams S, Veys P, **Czechowicz A**, and Cowan MJ. “A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.” Pediatr Transplant. 2014 Sep;18(6):609-16.
8. Dvorak CC, Horn BN, Puck JM, **Czechowicz A**, Shizuru JA, Ko RM, and Cowan MJ. “A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.” Pediatr. Transplant. 2014 Sep;18(6):602-8.
9. Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes D, Tate T, **Czechowicz A**, Kfoury Y, Ruchika F, Rossi D, Verdine G, Mansour M, Scadden D. “Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic cell-specific internalizing immunotoxin.” Nature Biotechnology. 2016 Jul;34(7):738-45. *[Designed and conducted several critical experiments, as well as contributed to data analysis and interpretation. Participated in critical revision of manuscript for important intellectual content.]*
10. Lu R, **Czechowicz A**, Seita J, Juang D, Weissman IL. “Clonal Stability of Hematopoietic Stem Cell Differentiation.” Proc. Natl. Acad. Sci. 2019 Jan 22;116(4):1447-1456. *[Guided scientific direction of section of project. Aided with execution of majority of experiments. Participated in interpretation of data and revision of manuscript for important intellectual content.]*
11. **Czechowicz A***, Palchaudhuri R*, Scheck A, Hu Y, Hoggatt J, Saez B, Pang W, Mansour M, Tate T, Chan YY, Walck E, Wernig G, Shizuru J, Winau F, Scadden D, Rossi D. “Selective Hematopoietic Stem Cell (HSC) Ablation using CD117 Antibody-Drug-Conjugates Enables Safe and Effective HSC Transplantation with Preservation of Immunity.” Nature Communications. 2019 Feb 6;10(1):617. *[Co-first author. Co-corresponding author.]*
12. Li Z, **Czechowicz A***, Scheck A, Rossi D, and Murphy P. “Robust Hematopoietic Chimerism and Donor-specific Tolerance after Non-genotoxic CD117 Antibody-Drug-Conjugate Conditioning in Fully MHC-mismatched Allotransplantation.” Nature Communications. 2019 Feb 6;10(1):616. *[Co-first author. Co-corresponding author. Spear-headed initial conception of project. Provided intellectual and technical assistance with design of all experiments and interpretation of data. Participated in all aspects of preparation of manuscript and was corresponding author through publication process.]*
13. Pang WW*, **Czechowicz A***, Logan AC, Bhardwaj R, Poyser J, Park CY, Weissman IL, Shizuru JA. “Anti-human CD117 antibody mediates depletion of normal and myelodysplastic syndrome hematopoietic stem cells.” Blood. 2019 May 9;133(19):2069-2078. *[Co-first author. Spear-headed initial conception of first half of the project. Generated data, analyzed results, and determined interpretation of data. Participated in critical revision of manuscript for important intellectual content.]*
14. Kwon H, Logan AC, Chhabra A, Pang WW, **Czechowicz A**, Tate K, Le A, Poyser J, Hollis R, Kelly BV, Thway TM, Kohn DB, Weissman IL, Prohaska SS, Shizuru JA. “Anti-human CD117 antibody-mediated bone marrow niche clearance in non-human primate and humanized NSG mice.” Blood.

- 2019 May 9;133(19):2104-2108. [*Spear-headed initial conception of section of the project. Provided technical assistance with portion of experiments and interpretation of data. Participated in critical revision of manuscript for important intellectual content.*]
15. Gao, C, Schroeder J, Xue F, Jing W, Cai Y, Scheck A, Subramaniam S, Rao S, Weiler H, **Czechowicz A**, Shi Q. “Non-genotoxic antibody-drug-conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.” Blood Advances. 2019 Sep 24; 3(18):2700-2711. [*Co-corresponding author. Spear-headed initial conception of project. Provided continued intellectual and technical assistance with design of all experiments and interpretation of data. Participated in critical revision of manuscript for important intellectual content.*]
 16. Kraft D, Walck E, Carrasco A, Crocker M, Song L, Long M, Najar S, Nadeem E, Imanbyev G, Mosse M, **Czechowicz A**, McCullough M. “The MarrowMiner: A Novel, Safe, Effective, and Minimally Invasive Device for the Harvest of Bone Marrow Cells.” Biology of Blood and Marrow Transplantation. 2020 Feb; 26(2):219-229. [*Provided intellectual and technical assistance with interpretation of data. Participated in writing manuscript and played an active role throughout publication process.*]
 17. Ho P, Zhang Z, Hayes M, Curd A, Dib C, Mayburn M, Tam F, Srivastava T, Hriniak B, Leonard S, Wang L, Tarighat S, Sim D, Fiandaca M, Coull J, Ebens A, Fordyce M, **Czechowicz A**. “Peptide Nucleic Acid-dependent artifact can lead to false-positive triplex gene editing signals.” PNAS. 2021 Nov 9; 118(45).
 18. Chan Y, Ho PY, Swartzrock L, Rayburn M, Nofal R, Thongthip S, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.” Transplantation and Cellular Therapy. 2023 Mar;29(3):164.e1-164.e9. Epub 2022 Aug 19. *Awarded 2022 Ernest McCulloch & James Till Award for the Best Basic Science article. Award presented at the 2023 Transplantation and Cell Therapy Meeting, Orlando, FL (02/18/2023).
 19. Igarashi KJ, Kucinski I, Chan YY, Tan TK, Khoo HM, Kealy D, Bhadury J, Hsu I, Ho PY, Niizuma K, Hickey JW, Nolan G, Bridge KS, **Czechowicz A**, Gottgens B, Nakauchi H, Wilkinson AC. “Physioxia improves the selectivity of hematopoietic stem cell expansion cultures.” Blood Advances. 2023 Jul 25;7(14):3366-3377. [*Spear-headed important component of the project showcasing disease-related application of HSC expansion approach. Provided intellectual and technical assistance with planning experiments and interpretation of data. Participated in critical revision of manuscript for important intellectual content.*]
 20. Denis M, Swartzrock L, Willner H, Bubb QR, Haslett E, Chan YY, Chen A, Krampf MR, **Czechowicz A**. “Hematopoiesis post anti-CD117 monoclonal antibody treatment in wild-type and Fanconi anemia settings.” Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2023.284275.
 21. Sharma A, **Czechowicz A**, Mavers M, Chao N, DiPersio J, Reddy P, Perales MA, Smith M. “Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force.” Transplant Cell Ther. 2024; Apr 10:S2666-6367(24)00344-0. [*Contributed to design of study, interpretation of data and writing and revision of manuscript.*]
 22. Swartzrock L, Dib C, Denis M, Willner H, Ho K, Haslett E, Han J, Pan W, Steele M, Brown B, Krampf MR, Girsan A, Blumenfeld YJ, El-Sayed YY, Roncarolo MG, MacKenzie TC, **Czechowicz A**. “In Utero Hematopoietic Stem Cell Transplantation for Fanconi Anemia.” Blood Adv. 2024 Jul 11:bloodadvances.2023011894. doi: 10.1182/bloodadvances.2023011894.

B. Non-peer reviewed journal articles, reviews, editorials, etc. (7 Total)

1. **Czechowicz A**, Kraft D, Weissman IL. “Development of a Robust Human Adaptive Immune System in CD34+ Enriched Peripheral Blood Transplanted Mice Through Use of Anti-Murine-C-Kit Monoclonal Antibody, ACK2.” The Stanford Biologist. 2005 May; 5: 79-86.

2. Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT; Workshop Participants (incl. **Czechowicz A**). "Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management." J Allergy Clin Immunol. 2009 Dec;124(6):1152-60. [Provided intellectual content. Participated in editing manuscript]
3. **Czechowicz A**, Weissman IL. "Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement." Immunol Allergy Clin North Am. Review. 2010 May;30(2):159-71. 2010.
4. **Czechowicz A**, Weissman IL. "Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement." Hematol Oncol Clin North Am. Review. 2011 Feb;25(1):75-87.
5. Cannon P, Asokan A, **Czechowicz A**, Hammond P, Kohn D, Lieber A, Malik P, Marks P, Porteus M, Verhoeven E, Weissman D, Weissman I, Kiem H. "Safe and Effective *In Vivo* Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development." Hum Gene Ther. 2021 Jan;32(1-2):31-42. [Provided intellectual content. Participated in editing manuscript]
6. Van Hentenryck M, Li Z, Murphy P, **Czechowicz A**. "Antibody-Based Immunosuppression and Conditioning in Transplantation." OBM Transplantation. Review. 2022; 6(3): 162.

VI. GRANTS AND FUNDED PROJECTS

A. Current Funding

09/2018 – 08/2024 -- Stanford Lorry Lokey Faculty Scholar

Project Title: *Faculty scholar award*. Role: PI.

09/2019 – 08/2024 -- Ludwig Center for Cancer Stem Cell Research and Medicine

Project Title: *Research support award*. Role: PI.

06/2020 – 12/2024 -- Rocket Pharmaceuticals, Ltd. Sponsored Research Agreement

Project Title: *Master Collaboration Agreement: Phase I/II FANCA exploratory studies*. Role: PI.

09/2020 – 07/2024 -- Jasper Therapeutics, Inc.

Project Title: *Treatment of Fanconi Anemia patients in Bone Marrow Failure requiring allogeneic transplant with non-sibling donors at Stanford Lucile Packard Children's Hospital*. Role: PI.

03/2023 – 03/2025 -- Fanconi Cancer Foundation

Project Title: *Development of In Utero Therapies for Fanconi Anemia*. Role: PI.

06/2023 – 05/2027 -- California Institute of Regenerative Medicine -- CLIN2

Project Title: *Reduced Intensity Conditioning with JSP191 Prior to TCRab+ T-cell/CD19+ B-cell Depleted Hematopoietic Stem Cell Transplant for Fanconi Anemia Patients*. Role: Co-I. Conceptualized this study and was critically involved in the development and execution of the work, as well as the grant writing, that led to this \$10.8M of funding.

08/2023 – 07/2025 -- American Society of Hematology Junior Faculty Scholar Award

Project Title: *Clonal Evolution in Patients with Fanconi Anemia*. Role: PI.

08/2023 – 07/2025 -- CURE Childhood Cancer

Project Title: *Development of Receptor Tyrosine Kinase-Targeting Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure of Pediatric Acute Myeloid Leukemia*. Role: PI.

12/2023 – 11/2025 – Falk Medical Research Trust Catalyst Award

Project Title: *Development of Novel DNA-guided Argonate Base Editing*. Role: PI.

7/2024 – 6/2025 – Diamond Blackfan Anemia Foundation

Project Title: *Development of Non-Genotoxic Anti-c-KIT Antibody-Based Conditioning for Hematopoietic Stem Cell Transplantation in DBA*. Role: co-PI.

B. Prior Funding

2008-2008 HHMI Research Training Fellowship
2008-2010 Paul and Daisy Soros Fellowship
2008-2010 Stanford Medical Scientist Training Program (MSTP)
2015-2017 NIH T32 training grant, Boston Children's Hospital

08/2018 – 12/2021 -- Fanconi Anemia Research Fund, Inc.

Project Title: *Development of a safe, completely non-genotoxic anti-c-Kit (CD117) antibody-based conditioning regimen for hematopoietic stem cell transplantation in Fanconi Anemia*. Role: PI.

10/2018 – 09/2020 -- Rocket Pharmaceuticals, Ltd. Sponsored Research Agreement

Project Title: *Master Collaboration Agreement for Pre-clinical Studies in Fanconi Anemia*. Role: PI.

10/2018 – 09/2021 -- Stanford Bio-X Seed Grant

Project Title: *Generation of Optimized Adeno-Associated Viruses (AAV) for Hematopoietic Stem Cell Transduction*. Role: PI.

01/2019 – 12/2019 -- Pediatric Cancer Research Foundation

Project Title: *Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for Pediatric Acute Myeloid Leukemia (AML)*. Role: PI.

05/2019 – 04/2020 -- Baxter Faculty Scholar, Donald E. and Delia B. Baxter Foundation

Project Title: *Combination Lentiviral Gene Therapy and Non-Genotoxic Anti-c-kit (CD117) Antibody Based Conditioning for Curative Treatment of Blood and Immune Diseases*. Role: PI.

08/2019 – 07/2023 -- National Institutes of Health – UG3

Project Title: *Delivery technologies for in vivo genome editing, PD/PI: Elliot Chaikof - Beth Israel Deaconess Medical Center*. Role: Co-I.

01/2020 – 12/2020 -- Stanford Maternal Child and Health Research Institute

Project Title: *Characterization of Novel Human HSC Cell Surface Receptors*. Role: PI.

01/2020 – 12/2021 -- Andrew McDonough B+ Foundation

Project Title: *Anti-KIT antibodies and immunotoxins as therapies and HSCT conditioning agents for pediatric AML*. Role: PI.

03/2020 – 06/2023 -- National Institutes of Health

Project Title: *AAV capsid engineering for enhancing gene transfer. PI: Mark Kay*. Role: Co-I.

06/2020 – 05/2024 -- Gabrielle's Angel Foundation

Project Title: *Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia (AML)*. Role: PI.

07/2020 – 06/2022 -- American Society of Transplantation and Cellular Therapy

Project Title: *Development of combination HSC base-editing and non-genotoxic antibody conditioning*. Role: PI.

07/2020 – 06/2022 -- National Blood Foundation

Project Title: *Determine genetic factors that regulate progression to bone marrow failure and myeloid neoplasia in Fanconi anemia*. Role: PI.

07/2020 – 09/2022 -- National Comprehensive Cancer Network

Project Title: *Development of anti-hKIT chimeric antigen receptor T-Cells as a dual hematopoietic stem cell transplantation (HSCT) conditioning and immunotherapeutic agent for cure of pediatric acute myeloid leukemia (AML)*. Role: PI.

09/2021 – 08/2023 -- Department of Defense

Project Title: *Development of Non-Genotoxic Hematopoietic Stem Cell Transplantation Regimens for Fanconi Anemia*. Role: PI.

09/2021 – 08/2023 -- Dunlevie Maternal-Fetal Medicine Center

Project Title: *In-Utero Therapies for Fanconi Anemia*. Role: PI.

10/2021 – 09/2022 -- Sophie's Neighborhood

Project Title: *Single Cell Transcriptomic Assessment of MCTO Patient Samples*. Role: PI.

11/2020 – 09/2023 -- Bill and Melinda Gate's Foundation

Project Title: *Exploitation of Hematopoietic Stem Cells Vulnerabilities to Enable in vivo Genome-editing for Correction of Blood and Immune Diseases*. Role: PI.

12/2020 – 12/2023 -- Hyundai Hope on Wheels

Project Title: *Development of anti-KIT antibodies as therapeutics and HSCT conditioning agents for pediatric leukemia*. Role: PI.

01/2022 – 11/2023 -- STRM.Bio, Sponsored Research Agreement

Project Title: *Megakaryocyte-derived extracellular vesicles (MkEVs) as delivery vehicles for Fanconi Anemia targeted gene therapy*. Role: PI.

VII. CLINICAL TRIALS

A. Current, On-going Trials with Active Role

01/2019 A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34 Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects with Fanconi Anemia Subtype A (GENE TRANSFER) (BMT 335). Sponsor: Rocket Pharmaceuticals. PI: Rajni Agarwal. Role: Prior PI, now transitioned to Associate Investigator.

02/2020 A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects with Fanconi Anemia Subtype A (GENE TRANSFER) (BMT 360). PI: Rajni Agarwal. Sponsor: Rocket Pharmaceuticals. Role: Prior PI, now transitioned to Associate Investigator.

03/2021 A Phase Ib/IIa Clinical Trial to Evaluate Use of TCR α B⁺ T-cell/CD19⁺ B-cell Depleted Hematopoietic Grafts and a Reduced-Intensity Preparative Conditioning Regimen Containing JSP191 to Achieve Engraftment and Blood Reconstitution in Patients with Fanconi Anemia (BMT 373). Sponsor: Matthew Porteus. PI: Rajni Agarwal. Role: Prior PI, now transitioned to Associate Investigator.

11/2021 Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102 (GENE TRANSFER) (BMT384 Rocket LTFU). Sponsor: Rocket Pharmaceuticals. PI: Rajni Agarwal. Role: Prior PI, now transitioned to Associate Investigator.

B. Current, On-going Trials with Less Active Role

04/2018 An Expanded Access Study Using the CliniMACS System to Offer Therapeutic Manipulated Grafts that are CD34 Cell Enriched and T Cell Depleted for Allogeneic Stem Cell Recipients (BMT 271). Sponsor: Rajni Agarwal. PI: Rajni Agarwal. Role: Investigator.

09/2019 Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34 Cells Transduced with a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects with PKD. (GENE TRANSFER) (BMT 355). Sponsor: Rocket Pharmaceuticals. PI: Ami Shah. Role: Investigator.

- 12/2019 A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in subjects with Transfusion-Dependent Beta-Thalassemia (GENE TRANSFER) (BMT 359). Sponsor: Vertex Pharmaceuticals. PI: Ami Shah. Role: Investigator.
- 11/2020 Phase 1/1b Study of T-allo10 Infusion after HLA-Partially Matched Related or Unrelated TCR α B⁺ T-cell/CD19⁺ B-cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (α B⁺ depleted-HSCT) in Children and Young Adults Affected by Hematologic Malignancies (BMT 367). Sponsor: Maria Grazia Roncarolo. PI: Alice Bertaina. Role: Investigator.

C. Current Trials Data Safety Monitoring Board

- 05/2020 In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM). Sponsor: Tippi Mackenzie. Role: Member.

VIII. PATENTS

1. Weissman IL, **Czechowicz A**, Bhattacharya D, Kraft D: "Immunodepletion of Host Bone Marrow for Improved Engraftment in Stem Cell Niche." Provisional Patent Filed 11/3/2006, International Patent Filed 11/2/2007, Patent Granted 9/11/2018.
2. Glucksmann A, Palestrant D, Tartaglia L, Mata-Fink J, **Czechowicz A**: "CRISPR-related Methods and Compositions." US Patent Filed 9/27/2013, International Patent Filed 9/26/2014, Published 8/18/2016.
3. Glucksmann A, Palestrant D, Tartaglia L, Mata-Fink J, **Czechowicz A**, Borisy A: "CRISPR-related Methods and Compositions with Governing gRNAs." US Patent Filed 11/7/2013, International Patent Filed 11/7/2014, Published 8/20/2015, Patent Granted 12/5/2017.
4. Scadden D, Palchaudhuri R, Rossi D, **Czechowicz A**: "Composition and methods for non-myeloablative conditioning." US Patent Filed 4/6/2016, Published 11/29/2018, Patent Granted 2/25/2020.
5. Edge A, Venuti M, **Czechowicz A**. "Expansion and differentiation of inner ear supporting cells and methods of use thereof." US Patent Filed 1/27/2017, Published 01/10/2019.
6. Rossi DJ, **Czechowicz A**, Murphy PM, Li Z. "Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation." US Patent Filed 3/29/2018, Published 6/18/2018.
7. Agarwal R, Long Boyle J, Cowan M, Dvorak C, Kwon H, Le A, Logan A, Pang W, Parkman R, Roncarolo M, Weinberg K, Shizuru J, Prohaska S, **Czechowicz A**, Weissman IL. "Hematopoietic Stem Cell Engraftment." US Patent Filed 12/7/2018, Published 12/2/2021.
8. Chan YY, **Czechowicz A**. "Use of immunosuppression to enable engraftment of hematopoietic stem cells." US Patent Filed 1/5/2023, Published 7/13/2023.
9. Bubb QR, **Czechowicz A**, Mackall C, Sotillo E, Richards R, Seir G. "Combinatorial Approaches for Targeting Hematopoietic Cells." Provisional Patent Filed 4/6/2024.

IX. EDITORIAL SERVICES: Ad Hoc Journal Reviewer

- 2017-2018 Current Cancer Drug Targets
 2018 Blood
 2020 Plos ONE
 2020 Human Gene Therapy
 2020-2021 JCI
 2021 Experimental and Molecular Pathology
 2022 Blood, American Society of Hematology Education Program

X. SERVICE AS A GRANT REVIEWER

- 2017 Reviewer, Stanford SPARK Program
 2018 Poster Reviewer, American Society for Gene and Cell Therapy (ASGCT)
 2019 Reviewer, NIH Molecular and Cellular Hematology (MCH) Study Section
 2019 Reviewer, Fanconi Anemia Research Fund (FARF)
 2021 Abstract Reviewer, American Society of Transplantation and Cell Therapy (ASTCT)
 2021 Abstract Reviewer, European Society for Blood and Marrow Transplantation (EBMT)
 2023 Abstract Reviewer, Fanconi Anemia Research Fund (FARF)
 2024 Abstract Reviewer, Fanconi Cancer Foundation (FCF)

XI. UNIVERSITY ADMINISTRATIVE SERVICES

A. Committee Service

| | |
|--------------|---|
| 2006-2007 | Medical School Admissions Student Recruitment Chair, Stanford University |
| 2008-2009 | Student Representative, Stanford University Faculty Senate |
| 2010-2011 | Student Member, Stanford School of Medicine Faculty Senate |
| 2010-2011 | Medical School Representative, Stanford Executive Presidents' Council |
| 2011 | Student Member, Committee on Curriculum and Academic Performance (CCAP) |
| 2011 | Student Member, MSTP Taskforce |
| 2011 | Student Member, Think Tank on Refining Medical Education |
| 2011-2012 | Student Representative, Stanford University Board of Trustees |
| 2018-present | Admissions Committee Member, Stanford MSTP, Stanford Biosciences (Immunology and Stem Cell Biology and Regenerative Medicine Graduate Programs) |
| 2021 | Junior Faculty Committee, Stanford LCME Institution Review |

B. Leadership Roles

| | |
|--------------|---|
| 2007-2009 | Class President, Stanford Medical Student Association |
| 2007-2008 | Co-President, Transplant Interest Group, Stanford School of Medicine |
| 2008-2011 | Co-President, Hematology/Oncology Interest Group, Stanford School of Medicine |
| 2009-2010 | Student Body President, Stanford Medical Student Association |
| 2010-2011 | Student Body Executive President, Stanford Medical Student Association |
| 2019-present | Co-lead, Blood Stem Cell Engineering & Transplantation Platform, Stanford Center for Definitive and Curative Medicine |
| 2020-present | Associate Director of Graduate Studies, Stem Cell Biology and Regenerative Medicine Graduate Student Program |

C. Education and Mentorship

| | |
|--------------|---|
| 2004-2005 | BioBridge Counselor, Stanford Biological Sciences Department |
| 2006-2008 | BioBridge Graduate Mentor, Stanford Biological Sciences Department |
| 2007 | Stanford Medical Youth Science Program Graduate Mentor, Stanford University |
| 2007-2008 | Teaching Assistant, Cells to Tissues (INDE 221), Stanford University School of Medicine |
| 2007-2009 | Teaching Assistant, Pediatric Chronic Disease (PEDS 281), Stanford University School of Medicine |
| 2008 | Group Leader, Stanford Wilderness Experience Activity Trip, Stanford University School of Medicine |
| 2016 | Lecturer, Various HMS Courses, Harvard Medical School |
| 2018-present | Lecturer, Various MD and PhD Courses, Stanford University School of Medicine: IMMUNOL 209, PEDS 227, PATH290, RADO204, STEMREM 200, and STEMREM 203 |
| 2018-present | Lecturer, Various Residency, Fellowship, Nursing and Administrator seminars, Stanford Children's, Lucile Packard Children's Hospital |
| 2019-present | Mentor, Stanford Women Association of Physician Scientists (SWAPS) Mentorship Program |
| 2020-present | Mentor, Stanford Stem Biology PhD First Year Mentorship Program |
| 2020-present | Committee Member, for Stanford PhD students including chairperson for PhD thesis defense |
| 2020-present | Course Director, IMMUNOL 223: Biology and Disease of Hematopoiesis |
| 2021-present | Mentor, Stanford MSTP BOOST and Stanford ADVANCE Undergraduate Institute and give annual lecture with Stanford EXPLORE program |
| 2021 | Group Faculty Mentor, Stanford Pediatrics Fellows Scholarship Academy |
| 2023 | Faculty Mentor, Stanford Hematology R25 |
| 2023-present | Faculty Mentor, Stanford <u>L</u> earners to <u>l</u> eaders in <u>U</u> rology, <u>N</u> ephrology, and non- <u>C</u> ancer <u>H</u> ematology (LAUNCH) TL1 Training Program |

XII. SERVICE TO PROFESSIONAL ORGANIZATIONS

A. Membership

| | |
|--------------|---|
| 2006-present | American Medical Association (AMA) |
| 2008-present | American Society of Hematology (ASH) |
| 2009-present | International Society for Stem Cell Research (ISSCR) |
| 2010-present | American Society of Bone Marrow Transplantation (ASBMT) |

2013-present American Society of Gene and Cell Therapy (ASGCT)
2018-present American Society for Transplantation and Cellular Therapy (ASTCT)
2019-present International Society Cell & Gene Therapy (ISCT)
2020-present International Society for Experimental Hematology (ISEH)

B. Committee Service

2010-2012 International Society for Stem Cell Research (ISSCR): Junior Investigator Committee
2020-present American Society for Transplantation and Cellular Therapy: Talent Acquisition Task Force
2021-present Fanconi Anemia Clinical Care: Guidelines Consensus Committee (FACCGCC)
2022-present Fanconi Anemia Cancer Consortium (FACC)
2022-present American Society for Gene and Cell Therapy (ASGCT): Stem Cell Committee
2022-present American Society for Gene and Cell Therapy (ASGCT): Trainee Committee
2023-present American Society for Gene and Cell Therapy (ASGCT): Fetal Cell and Gene Therapy Committee (Inaugural member)

XIII. PRESENTATIONS

A. Invited Speaker / Moderator:

1. Invited Keynote Speaker: "Development of Antibody-based Conditioning Agents for Transplant: Towards More Targeted Therapy?" presented at the 2017 British Society of Bone and Marrow Transplantation (BBMT), London, England (05/16/2017).
2. Invited Guest Translational Group Speaker: "Discovery of Non-toxic Conditioning Regimens for Stem Cell Therapies" presented at the National Institutes of Health (NIH), Washington, DC (4/27/2018).
3. Invited Keynote Speaker Bridges Graduation: "Hematopoietic Stem Cells: A Powerful Platform for The Treatment of Blood and Immune Diseases" presented at San Jose State University (SJSU), San Jose, CA (5/3/2018).
4. Invited Guest Seminar Speaker: "Discovery of Non-Toxic Conditioning Regimens for Stem Cell Therapies" presented at the Blood Center of Wisconsin, Waukesha, WI (11/6/2018).
5. Invited Guest Research Seminar Speaker: "Discovery of Non-Toxic Conditioning Regimens for Stem Cell Therapies" presented at Nationwide Children's Hospital, Columbus, OH (11/9/2018).
6. Invited Symposium Speaker: "Development of Anti-CD117 mAb Conditioning Strategies for Hematopoietic Stem Cell Transplantation" presented at the 2018 Haploidentical Transplantation Symposium (HAPLO2018), San Diego, CA (11/29/2018).
7. Invited Pediatric Grand Rounds, Harvey J. Cohen Endowed Lectureship in Pediatrics Speaker: "Development of Safer Conditioning Strategies for Hematopoietic Stem Cell Transplantation" presented at Lucile Packard Children's Hospital Stanford, Stanford, CA (1/11/2019).
8. Invited Panelist: "Novel Therapeutic Targets" presented at the 2019 In Vivo Gene Therapy & Genome Editing Summit, Miami, FL (3/18/2019).
9. Invited Symposium Speaker: "Updates on the Ongoing Clinical Trials in the US" presented at the 2019 Fanconi Anemia Gene Therapy Symposium, South San Francisco, CA (4/19/2019).
10. Invited Family Camp Speaker: "Update on US Gene Therapy Trial for FA" presented at Camp Sunshine, Casco, ME (6/23/2019).
11. Invited Symposium Speaker: "Novel Conditioning Regimen: Antibody (c-KIT) Conditioning for Non-Malignant Disease" at the 2019 Cord Blood Connect International Congress, Orlando, FL (9/13/2019).
12. Invited Conference Speaker: "Future of Blood and Immune Replacement" presented at the Arc Fusion Future of Humans Summit, Boston, MA (12/4/2019).
13. Advisory Board Member Presenter: "Antibody-based Strategies" presented at the CSL Behring Cell Transplant Board Meeting, Miami, FL (1/17/2020).
14. Invited Symposium Speaker: "Updates on the Ongoing Clinical Trials in the US" presented virtually at the 2020 Fanconi Anemia Gene Therapy Symposium, Held online (5/1/2020).
15. Invited Meeting Speaker: "Achieving Selective and Precise In Vivo Targeting and Gene Editing: Key Features of HSCs and Their Environment" presented virtually at the National Institutes of Health -the Bill & Melinda Gates Foundation Expert Scientific Roundtable Webinar Meeting, Held online (5/11/2020).
16. Invited Roundtable Chair: "Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development" at the National Institutes of Health -the Bill & Melinda Gates Foundation Expert Scientific Roundtable Webinar Meeting (5/11/2020)

17. Invited Symposium Speaker: “Improving HSCT Transplantation by Novel Conditioning - How it applies to Allogeneic HSCT” presented virtually at the American Society for Gene and Cell Therapy, Held online (5/12/2020).
18. Invited Seminar Speaker: “Enabling Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the UC Berkeley - Innovative Genomics Institute (IGI) "SIP" Seminar Series (5/19/2020).
19. Invited Speaker: “Stanford Antibody Conditioning Trial” presented virtually at the 2020 Annual Fanconi Anemia Family Meeting/Camp Sunshine, Held online (6/26/2020).
20. Invited Speaker: “Gene Therapy: Stanford Trial & Rocket Pharmaceuticals, Inc.” presented virtually at the 2020 Annual Fanconi Anemia Family Meeting/Camp Sunshine, Held online (6/29/2020).
21. Invited Conference Speaker: “Selective Hematopoietic Stem Cell Ablation using CD117-Antibody-Drug-Conjugates Enables Safe and Effective Transplantation with Immunity Preservation” presented virtually at the 2020 World’s Definitive Antibody-Drug Conjugate Conference, Held online (9/18/2020).
22. Invited Roundtable Chair: “In Utero Gene Therapy Using AAV vectors” at the 2020 International Conference on In Utero Transplantation and Gene Therapy, Held online (10/1/2020).
23. Invited Conference Speaker: “In utero gene Therapy for Fanconi Anemia” presented virtually at the 2020 International Conference on In Utero Transplantation and Gene Therapy, Held online (10/2/2020).
24. Invited Panel Speaker: “Medicine and Healthcare” presented virtually at the Silicon Valley Poland Days, Science and Technology Symposium (10/22/2020).
25. Invited Guest Grand Rounds Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases; Learnings from the Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at City of Hope Grand Rounds, Held online (11/5/2020).
26. Invited Symposium Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the 2020 Sickle Cell Transplant Advocacy and Research Alliance (STAR) Annual Meeting, Held online (11/9/2020).
27. Invited Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the 5th Annual Center for Definitive and Curative Medicine (CDCM) Symposium, Held online (2/25/2021).
28. Invited Speaker: “Progress Towards Safe, Curative Treatment of Blood & Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the 2021 World Antibody-Drug Conjugate (ADC) Europe Annual Meeting, Held online (3/10/2021).
29. Invited Speaker: “Antibody-based conditioning in SCID and beyond” presented virtually at the 2021 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, Held online (3/16/2021).
30. Invited Faculty Panel: “Showcasing Your Strengths” presented virtually at the Stanford MSTP AUI/BOOST Program, Held online (4/8/2021).
31. Invited Moderator: “Faculty Talks” presented virtually at the 12th Annual Stanford School of Medicine Pediatrics Research Retreat, Held online (4/21/2021).
32. Invited Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the Howard Hughes Medical Institute (HHMI), R3 - Replace, Repair, Regenerate Symposium, Held online (7/21/2021).
33. Invited Speaker: “Gene Therapy for Fanconi Anemia: Interim Results from RP-L102 Global Clinical Trials” presented virtually at the Gene Therapy in Fanconi Anemia: Placing and Replacing FA Genes, 2021 Fanconi Anemia Research Foundation (FARF) Symposium, Held online (7/8/2021).
34. Invited Speaker: “Stem Cell Transplantation - Where we are now and where we hope to be” presented virtually at the Science Polish Perspectives Meetup USA, Held online (9/17/2021).
35. Invited Speaker: “Regenerative Medicine Session Speaker” presented virtually at the University of California- San Diego (UCSD), Sanford Stem Cell Symposium, Held online (10/15/2021).

36. Invited Speaker: “Individualized Conditioning Regimens: Antibody Based Conditioning” presented virtually at the Memorial Sloan Kettering Cancer Center (MSKCC), Transplant and Cellular Therapy Options for Non-Malignant Hematologic Disorders Symposium, Held online (10/15/2021).
37. Invited Speaker: “ab T-cell/CD19 B-cell Depleted Haploidentical HSCT Combined with Antibody Conditioning Regimen for Fanconi Anemia” presented virtually at the 1st International Symposium on $\alpha\beta$ T-cell/CD19 B-cell depleted Haploidentical Stem Cell Transplantation, Held online (10/20/2021).
38. Invited Panel Discussion Moderator: “In Utero Therapies Panel Discussion” presented virtually at the CERSI-FDA Workshop on Prenatal Somatic Cell Gene Therapies, Held online (10/26/2021).
39. Invited Panelist: “Regenerative Medicine and Stem Cell Therapies” presented at the 2021 Convergence Forum, Harwich, MA (10/29/2021).
40. Invited Faculty Speaker: “Compete or perish – HSC dynamics in Fanconi Anemia” presented virtually at the Stanford ReMS Regenerative Medicine Seminar Series, Held online (11/4/2021).
41. Invited Speaker: “Stem Cell and Gene Editing Therapies” presented virtually at the Fetal Therapy: Current Status and Future Directions — Stanford Symposium, Held online (11/9/2021).
42. Invited Speaker: “Breaking biotech's barriers” presented virtually at the 2021 STAT Summit, Held online (11/16/2021).
43. Invited Lecturer: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the Institute of Transfusion Medicine of Goethe University and German Red Cross Blood Service, Held online (11/17/2021).
44. Invited Speaker: “Fanconi Anemia: From disease biology to current treatments” presented virtually at the Prime Medicine Science Seminar Series, Held online (11/30/2021).
45. Invited Panelist: Poland Days in Silicon Valley 2021 – Post-Pandemic Accelerated Digital World, Held online (12/8/2021).
46. Invited Speaker: “Development of New Treatments for Fanconi Anemia: Gene Therapy and Antibody-Based Stem Cell Transplantation” presented at the National Heart, Lung and Blood Institute’s Fellowship Hematology Conference, Held online (1/5/2022).
47. Invited Speaker: “Fanconi Anemia: From disease biology to current treatments” presented virtually at the Rome Therapeutics Seminar and Roundtable Discussion, Held online (3/11/2022).
48. Invited Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the CSL Research Symposium, Held online (4/6/2022).
49. Invited Oral Abstract Session Moderator: “for the Oral Abstract - Session C - Immune and Gene Therapy” presented at the 2022 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Salt Lake City, UT (4/23/2022).
50. Invited Speaker: “Advancing Hematopoietic Cell Therapies” presented at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, San Francisco, CA (6/14/2022).
51. Invited Speaker: “Stanford Children’s Fanconi Anemia Clinical Trial Using JSP191 Antibody Conditioning and TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depletion” presented at the 2022 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Austin, TX (9/11/2022).
52. Invited Co-Host: “Special People in Cellular Immunotherapy – SPICI Conference” hosted by Chardan, Berkeley, CA (9/11-9/13/2022).
53. Invited Keynote Speaker: “Hematopoietic Stem Cell Transplantation/Preconditioning” presented at the William Blair Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event, Held online (9/29/2022).
54. Invited Speaker: “Gene Therapy for Fanconi Anemia” presented at the 2022 Society of Hematologic Oncology (SOHO) Saudi Arabia Virtual Meeting, Held online (10/10/2022).
55. Invited Speaker: "Development of Improved Cell and Gene Therapies for Fanconi Anemia and Beyond" presented at the Hematology Research Seminar Series at St. Jude Children’s Research Hospital in the departments of Hematology and BMT, Held online (10/21/2022).
56. Invited Bridges Speaker: “Novel Conditioning Regimens for Hematopoietic Cell Transplantation: Progress Towards Safe, Curative Treatment of Blood and Immune Diseases presented virtually at San Jose State University (SJSU), Held online (10/31/2022).
57. Invited Seminar Speaker: “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Learnings from the Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation” presented virtually at the Capstan Therapeutics Science Seminar Series, Held online (12/2/2022).

58. Invited Speaker: “Transplant Approaches for Bone Marrow Failure Syndromes” presented at the 2023 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, FL (2/16/2023).
59. Invited co-chair at the “DEI Roundtable” session: moderated at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Los Angeles, CA (5/18/2023).
60. Invited Co-chair at the “Emerging Opportunities in Cellular Therapies Derived from Stem Cells” session: moderated at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Los Angeles, CA (5/20/2023).
61. Invited Speaker: “FA Center of Excellence Presentation - Stanford University” and participant on “FA Center of Excellence Panel” presented at Camp Sunshine, Casco, ME (6/27/2023).
62. Invited Speaker: “Educational Webinar Series on BMF - Gene Therapy for Fanconi Anemia” presented at the North American Pediatric Aplastic Anemia Consortium virtual event, Held online (9/18/2023).
63. Invited Co-Host: “Special People in Cellular Immunotherapy – SPICI Conference” hosted by Chardan, La Jolla, CA (9/10-9/12/2023).
64. Invited Symposium Session Co-Chair: “Gene Therapy, Gene Editing and Beyond FA” at the 2023 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Vancouver, Canada (10/1/2023).
65. Invited Speaker: “Lentiviral-Mediated Gene Therapy for Fanconi Anemia [Group A]: Updated Results From Global RP-L102 Clinical Trials” presented at the 2023 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Vancouver, Canada (10/1/2023).
66. Invited Symposium Co-Organizer: NIH Science of Conditioning Workshop, Held online (1/25/2024).
67. Invited Speaker: “Earliest Work on CD117 (c-Kit) Antibody Conditioning” presented at the NIH Science of Conditioning Workshop, Held online (1/25/2024).
68. Invited Session Moderator: “Focus on Bone Marrow Failure Syndromes” at the 2nd Annual International Symposium on TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Haploidentical HSCT, Stanford, CA (1/31/2024).
69. Invited Panelist: “CDCM Translational Success From the Bench to the Bedside – Story of Treating Fanconi Anemia” at the 8th Annual Stanford Center for Definitive and Curative Medicine Symposium, Stanford, CA (3/13/2024).
70. Invited Moderator: “Faculty Talks” presented virtually at the 12th Annual Stanford School of Medicine Pediatrics Research Retreat, Held online (4/21/2021).
71. Invited Speaker: “In Utero Transplantation for Fanconi Anemia” presented at the Stanford Dunlevie Maternal Fetal Medicine Center Fetal Therapy Symposium, Held online (5/2/2024).
72. Invited Co-chair at the “Prospects for Prenatal Gene and Cell Therapy” session: moderated at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Baltimore, MD (5/8/2024).
73. Invited Co-chair at the “Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies” session: moderated at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Baltimore, MD (5/8/2024).
74. Invited Speaker: “Outstanding New Investigator Talk,” 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Baltimore, MD (5/10/2024).
75. Invited Speaker: “Innovative Non-Genotoxic Cell and Gene Therapies for Fanconi Anemia” presented at the 9th Annual Symposium on Cell and Gene Therapy, Centre for Stem Cell Research (CSCR), Vellore, India (8/1/2024).
76. Invited Symposium Session Co-Chair: “Gene Therapy, Gene Editing and Beyond FA” at the 2024 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Charlotte, NC (10/1/2024).
77. Invited Speaker: “Innovative In Utero Therapies for Fanconi Anemia,” 2024 8th International Fetal Immunology and Transplantation Society (IFeTIS) Conference, Wake Forest, NC (11/2/2024).

B. Abstracts: Oral Presentations (Last 5 Years; Total of 42):

1. **Czechowicz A**, Cory J, Shah D, Roncarolo M. “Non-genotoxic conditioning for hematopoietic cell transplantation in Fanconi Anemia.” Abstract. A Czechowicz presented at the 2019 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Chicago, IL (9/19/2019).
2. **Czechowicz A**, Roncarolo MG, Beard B, Choi G, Law K, Nicoletti E, Schwartz JD, Soni S. “A Phase I Study of Lentiviral-mediated Ex-vivo Gene Therapy for Pediatric Patients with Fanconi Anemia,

- Complementation Group-A: Initial Patient Experience.” Abstract. A Czechowicz presented at the 2019 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Chicago, IL (9/21/2019).
3. **Czechowicz A**, Rio P, Bueren J, Beard B, Nicoletti E, Schwartz JD, and Soni S. “Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene Insertion in Human Stem and Progenitor Cells.” Abstract. S Soni presented at the 2019 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Annual Meeting, Orlando, FL (2/20/2020).
 4. **Czechowicz A**, Agarwal R, Soni S, Beard B, Law K, Nicoletti E, Rio P, Bueren J, Schwartz J, Roncarolo M. “Preliminary Results from a U.S. Phase I Study of Lentiviral Ex-vivo Gene Therapy for Patients with Fanconi Anemia Type A.” Abstract. A Czechowicz presented virtually at the 2020 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (9/16/2020).
 5. **Czechowicz A**, Pang W, Van Hentenryck M, Thongthip S, Chan S, Walck E, Scheck A, Dejene B, Kwon H, Le A, Dvorak C, Long-Boyle J, Brown J, Logan A, Parkman R, Weissman I, Bertaina A, Weinberg K, Roncarolo M, Shizuru J, Agarwal R. “JSP191 Antibody Conditioning for Hematopoietic Cell Transplantation: Anticipating a New Therapy for Fanconi Anemia” Abstract. A Czechowicz presented virtually at the 2020 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (9/16/2020).
 6. MacKenzie T, Frascoi M, Sper R, Lianoglou B, Gonzalez-Velez J, Dvorak C, Kharbanda S, **Czechowicz A**, Vichinsky E. “In utero stem cell transplantation in patients with hemoglobin disorders: anticipating a new therapy for Fanconi Anemia.” Abstract. T MacKenzie presented virtually at the 2020 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (9/16/2020).
 7. **Czechowicz A**, Agarwal R, Sevilla J, Rio P, Navarro S, Beard B, Law K, Choi G, Zeini M, Nicoletti E, Wagner J, Booth C, Schwartz J, Bueren J, Roncarolo M. “Gene Therapy for Fanconi Anemia, Complementation Group A: Updated Results from Ongoing Global Clinical Studies of RP-L102.” Abstract. A Czechowicz presented virtually at the 2020 American Society of Hematology (ASH) Annual Meeting, Held online (12/7/2020).
 8. **Czechowicz, A**. “Gene Therapy for Fanconi Anemia [Group A]: Interim Results from RP-L102 Global Clinical Trials.” Abstract. A Czechowicz presented virtually at the 2021 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (7/8/2021).
 9. **Czechowicz A**, Booth C, Agarwal R, , Zubicaray J, Río P, Navarro S, Ancliff P, Sebastian E, Law K, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Wagner J, Rao G, Thrasher A, Schwartz J, Bueren J, Roncarolo M, Sevilla J. “Ex vivo Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2022 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Washington, DC (5/16/2022).
 10. Nofal R, Chan YY, Sen S, Figueroa UJ, Hoang H, Thongthip S, Choi G, Nicoletti E, Schwartz J, Weinberg K, Rodriguez A, Agarwal R, Roncarolo MG, **Czechowicz A**. “Assessment of hematopoietic stem, progenitor and immune cells in Fanconi Anemia-Type A patients after ex vivo lentiviral FANCA gene therapy with RP-L102.” Abstract. R Nofal presented at the 2022 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Austin, TX (9/10/2022).
 11. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, Navarro S, Chetty K, O’Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Wagner JE, Rao GR, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. “Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the Best Abstracts at the Tandem meeting session, 2023 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Annual Meeting, Orlando, FL (2/20/2023). **Second Place Award for Best Abstract*.

12. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, S Navarro, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao GR, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. "Lentiviral-mediated Gene Therapy for Fanconi Anemia [Group A]: Results from Global RP-L102 Clinical Trials." Abstract. A Czechowicz presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Los Angeles, CA (5/18/2023).
13. Swartzrock L, Dib C, Willner H, Haslett E, Krampf M, Girsen A, Blumenfeld Y, El-Sayed Y, Roncarolo MG, MacKenzie TC, **Czechowicz A**. "In Utero Hemopoietic Stem Cell Transplantation for Fanconi Anemia." Abstract. A Czechowicz presented at the 2023 7th International Fetal Immunology and Transplantation Society IFeTIS Conference, Edinburgh, Scotland (6/16/2023).
14. Swartzrock L, Dib C, Willner H, Haslett E, Krampf M, Girsen A, Blumenfeld Y, El-Sayed Y, Roncarolo MG, MacKenzie TC, **Czechowicz A**. "In Utero Hemopoietic Stem Cell Transplantation for Fanconi Anemia." Abstract. L Swartzrock presented at the 2023 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Vancouver, Canada (9/30/2023).
15. Agarwal R, Bertaina A, Soco C, Saini G, Kunte N, Chan YY, Willner H, Krampf M, Nofal R, Barbarito G, Sen S, Felber M, Ven Hentenryck M, Walck E, Scheck A, Thongthip S, Logan A, Dougall K, Bouge A, Boelens JJ, Long-Boyle J, Weissman I, Shizuru J, Pang W, Weinberg K, Parkman R, Roncarolo M, Porteus M, **Czechowicz A**. "Radiation and Busulfan-free Transplant Using JSP191 Antibody Conditioning and TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Grafts." Abstract. R Agarwal presented at the 2023 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Vancouver, Canada (9/30/2023).
16. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, S Navarro, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao GR, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. "Lentiviral-mediated Gene Therapy for Fanconi Anemia [Group A]: Results from Global RP-L102 Clinical Trials." Abstract. A Czechowicz presented at the 2023 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Vancouver, Canada (10/1/2023).
17. Swartzrock L, Dib C, Willner H, Haslett E, Ho K, Krampf M, Girsen A, Blumenfeld Y, El-Sayed Y, Roncarolo MG, MacKenzie TC, **Czechowicz A**. "In Utero Hemopoietic Stem Cell Transplantation for Fanconi Anemia." Abstract. L Swartzrock presented at the 6th Annual Stanford Maternal and Child Health Research Institute (MCHRI) Symposium, Stanford, CA (10/19/2023).
18. Agarwal R, Bertaina A, Soco C, Saini G, Kunte N, Hiroshima L, Chan YY, Willner H, Krampf M, Nofal R, Barbarito G, Sen S, Felber M, Ven Hentenryck M, Walck E, Scheck A, Thongthip S, Logan A, Dougall K, Bouge A, Boelens JJ, Long-Boyle J, Weissman I, Shizuru J, Pang W, Weinberg K, Parkman R, Roncarolo M, Porteus M, **Czechowicz A**. "Radiation and Busulfan-free Hematopoietic Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia." Abstract. R Agarwal presented at the 2023 American Society of Hematology (ASH) Annual Meeting, San Diego, CA (12/9/2023).
19. Bubb QR, Balood M, Seir G, Swartzrock L, Haslett E, Ho K, Wiltz S, Sotillo E, Richards RM, Gruber TA, Mackall CL, **Czechowicz A**. "Development of Extracellularly Linked Concatemeric Trivalent Cytokine (ELeCTriC) Chimeric Antigen Receptor (CAR) T-Cells as Dual Conditioning and Immunotherapeutic Agents." Abstract. QR Bubb presented at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Baltimore, MD (5/8/2024).
20. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, S Navarro, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Rothe M, Bastone A, John-Neek P, Schambach A, Wang W, Choi G, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao GR, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. "Lentiviral-Mediated Gene Therapy (RP-L102) for Fanconi Anemia [Group A] is Associated with Polyclonal Integration Patterns in the Absence of Conditioning." Abstract. A

Czechowicz presented at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Baltimore, MD (5/10/2024).

21. Agarwal R, Bertaina A, Porteus M, **Czechowicz A**. “Haploidentical Transplant Experience for Patients with Fanconi Anemia – Can We Eliminate TBI and Busulfan From Conditioning Regimens?” Abstract. R Agarwal to present at the 2024 Fanconi Cancer Foundation (FCF) Scientific Symposium, Charlotte, NC (9/21/2024).

C. Abstracts: Posters Presentations (Last 5 Years; Total of 29):

1. Gao C, Schroeder JA, Xue F, Jing W, Subramaniam S, Weiler H, **Czechowicz A**, Shi Q. “Using Non-Genotoxic, Antibody-drug-conjugate Conditioning Enables Safe and Effective Platelet-specific FVIII Gene Therapy of Hemophilia A.” Abstract. Q Shi presented at the 2019 Congress of International Society on Thrombosis and Haemostasis (ISTH), Melbourne, Australia (7/7/2019).
2. **Czechowicz A**, Rio P, Bueren J, Beard B, Nicoletti E, Schwartz JD, Soni S. “Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene Insertion in Human Stem and Progenitor Cells.” Abstract. A Czechowicz presented at the 2019 American Society of Hematology (ASH) Annual Meeting, Orlando, FL (12/8/2019).
3. Bertaina A, Bacchetta R, Lewis D, Grimm P, Shah A, Agarwal R, Conception W, **Czechowicz A**, Bhatia N, Lahiri P, Weinberg K, Parkman R, Porteus M, Roncarolo M. “ $\alpha\beta$ T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplantation: A New Platform for Curing Rare and Monogenic Disorders.” Abstract. A Bertaina presented at the 2020 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, FL (2/20/2020).
4. Van Hentenryck M, Thongthip S, Stone S, Hwang T, Kristovich K, Velez-Bartolomei F, Lee CU, Chu J, Narla A, Sakamoto K, Glader B, Balasa V, Rao L, Agarwal R, Weinberg K, Bertaina A, **Czechowicz A**. “Treatment Resistance in a Fanconi Anemia Mosaic Patient with Myelodysplastic Syndrome.” Abstract. M Van Hentenryck presented virtually at the 2020 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (9/15/2020).
5. Agarwal R, Weinberg K, Kwon H, Le A, Long-Boyle J, Kohn D, Bradford K, De Oliveira S, Bertaina A, **Czechowicz A**, Porteus M, Shyr D, Weinacht K, Shah A, Mavers M, Merkel M, Brown J, Dvorak C, Parkman R, Roncarolo M, Shizuru J. “First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency.” Abstract. R Agarwal presented virtually at the 2020 American Society of Hematology (ASH) Annual Meeting, Held online (12/5/2020).
6. R Agarwal, CC Dvorak, TB Moore, K Weinberg, HS Kwon, J Long-Boyle, A Le, K Truong, D Kohn, K Bradford, S de Oliveira, A Bertaina, **A Czechowicz**, M Porteus, A Shah, D Shyr, K Weinacht, M Mavers, E Merkel, A Vargas, N Harada, JW Brown, WW Pang, R Parkman, MG Roncarolo, JA Shizuru. “Non-Genotoxic Anti-CD117 Transplant Conditioning in Infants with Newly Diagnosed Severe Combined Immune Deficiency.” Abstract. J Shizuru presented virtually at the 2021 Transplantation and Cellular Therapy (TCT) Meeting of ASTCT and CIBMTR, Held online (2/8/2021).
7. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Rio P, Navarro S, Ancliff P, Beard B, Law K, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Rao G, Wagner J, Schwartz J, Bueren J, Roncarolo M. “Gene Therapy for Fanconi Anemia [Group A]: Preliminary Results of Ongoing RP-L102 Clinical Trials,” Abstract. A Czechowicz presented virtually at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Held online (5/11/2021).
8. Nofal R, Chan Y, Sen S, Hoang H, Thongthip S, **Czechowicz A**. “Development of A Toolbox of Research Studies for Fanconi Anemia.” Abstract. R Nofal presented virtually at the 4th Annual

Stanford Maternal and Child Health Research Institute (MCHRI) Symposium, Held online (10/28/2021).

9. **Czechowicz A**, Sevilla J, Agarwal R, Booth C, Zubicaray J, Río P, Navarro S, Ancliff P, Sebastian E, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Wagner J, Rao G, Thrasher A, Schwartz J, Bueren J, Roncarolo M. “Gene Therapy for Fanconi Anemia [Group A]: Interim Results of RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2021 American Society of Hematology (ASH) Annual Meeting, Atlanta, GA (12/13/2021).
10. Bubb Q, Cheung C, Seir G, Swartzrock L, Richards R, Mackall C, **Czechowicz A**. “Development of hKIT Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure of Pediatric Acute Myeloid Leukemia.” Abstract. Q Bubb presented at the 2022 National Comprehensive Cancer Network (NCCN) Annual Conference, Held online (3/31/2022).
11. Chan Y, Nofal R, Ho P, Thongthip S, Rayburn M, Swartzrock L, Scheck A, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.” Abstract. A Czechowicz presented at the 2022 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Salt Lake City, UT (4/24/2022).
12. Chan Y, Nofal R, Ho P, Thongthip S, Rayburn M, Swartzrock L, Scheck A, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.” Abstract. A Czechowicz presented at the 2022 Joint ASTCT – EBMT Basic and Translational Scientific Retreat, Vail, CO (5/25/2022).
13. Chan Y, Nofal R, Ho P, Thongthip S, Rayburn M, Swartzrock L, Scheck A, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.” Abstract. A Czechowicz presented at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, San Francisco, CA (6/15/2022).
14. Chan Y, Nofal R, Ho P, Swartzrock L, Rayburn M, Nofal R, Thongthip S, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia Mice through Antibody-Mediated Hematopoietic Stem Cell Transplantation.” Abstract. A Czechowicz presented at the 2022 American Society of Hematology (ASH), New Orleans, LA (12/11/2022).
15. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, Navarro S, Chetty K, O’Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Wagner JE, Rao G, Thrasher A, Schwartz J, Roncarolo M, Bueren J. “Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2022 American Society of Hematology (ASH), New Orleans, LA (12/12/2022).
16. Kunte N, Din H, Saina G, Istomina E, Dougall K, MacDonald B, Bartolome R, Olsen A, Bouge A, **Czechowicz A**, Agarwal R, Porteus M. “Implementation of a Phase 1b/2a Clinical Trial for Fanconi Anemia Patients Using JSP191 Antibody Conditioning and TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Grafts: A Center Experience.” Abstract. N Kunte presented at the 2023 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, CA (2/16/2023).
17. Agarwal R, **Czechowicz A**, Felber M, Klinger E, Saini G, Kunte N, Nofal R, Weinacht K, Klein O, Shyr D, Weinberg K, Roncarolo M, Bertaina A. “TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Haploidentical Stem Cell Transplantation for Fanconi Anemia: The Stanford Children’s Experience” Abstract. A Czechowicz presented at the 2023 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, CA (2/16/2023).
18. Agarwal R, Bertaina A, Nofal R, Saina G, Kunte N, Sen S, Chan Y, Willner H, Felber M, Krampf M, Ven Hentenyck M, Walck E, Scheck A, Thongthip S, Logan A, Dougall K, Bouge A, Boelens JJ, Long-Boyle J, Parkman R, Weissman I, Shizuru J, Pang W, Roncarolo M, Porteus M, **Czechowicz A**. “Initial Results from Stanford Children’s Fanconi Anemia Clinical Trial Using JSP191 Antibody

Conditioning and TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Grafts.” Abstract. R Agarwal presented at the 2023 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, CA (2/16/2023).

19. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, Navarro S, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Wagner JE, Eide C, Rao G, Thrasher A, Schwartz J, Roncarolo M, Bueren J. “Lentiviral-mediated Gene Therapy for Fanconi Anemia [Group A]: Results from RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2022 American Society of Pediatric Hematology and Oncology (ASPHO), Fort Worth, TX (5/12/2023). *Selected for poster highlight (5/10/23)*.
20. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, Navarro S, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Rothe M, Bastone AL, John-Neek P, Schambach A, Wang W, Choi G, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao G, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. “Lentiviral-mediated Gene Therapy (RL-L102) for Fanconi Anemia [Group A] is Associated with Polyclonal Integration Pattern in Absence of Conditioning.” Abstract. A Czechowicz to present at the 2024 Fanconi Cancer Foundation (FCF) Scientific Symposium, Charlotte, NC (9/19/2024).

XIV. COMMUNITY SERVICE and INTERNATIONAL WORK

| | |
|------|--|
| 2005 | Roatan Clinical and Public Health Intern, Roatan, Honduras |
| 2011 | Little Children of the World Volunteer, Dumaguete City, Philippines |
| 2011 | Hematology Visiting Elective Student Volunteer, Christian Medical College, Vellore, India |
| 2014 | Stem Cell Transplant Visiting Elective Resident Volunteer, Hôpital Necker Enfants Malades, Paris, France |